Skip to content
Bored Studies
RecruitingPhase 1

A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults

UCB Biopharma SRL · NCT07290036

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 1
Target enrollment
392
US sites recruiting
30
Study start
December 10, 2025
Record last updated
July 6, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

To demonstrate that bimekizumab administered intravenously is noninferior to subcutaneous administration.

Being studied: Bimekizumab regimen 1 iv; Bimekizumab regimen 2 iv; Bimekizumab regimen 3 sc

Conditions: Psoriatic Arthritis; Axial Spondyloarthritis

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Be 18+ years old and legally able to consent
  • Have active psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA), suitable for bimekizumab treatment
  • Weigh between 45-100 kg (females) or 50-100 kg (males).
  • Be biologic disease-modifying anti-rheumatic drug (bDMARD)-naïve or have stopped bDMARDs ≥3 months or 5 half-lives ago

Exclusion Criteria

  • Serious organ system disorders (e.g., heart, liver, kidney, gastrointestinal, neuro)
  • Severe psychiatric issues or substance abuse in the past year
  • Recent or chronic infections, including tuberculosis (TB) or nontuberculous mycobacterium (NTMB)
  • Other inflammatory diseases (e.g., rheumatoid arthritis (RA), lupus, inflammatory bowel disease (IBD))
  • Recent live vaccines (within 8 weeks) or Bacillus Calmette-Guerin (BCG) (within 1 year)
  • Recent use of glucagon-like peptide-1 (GLP-1) agonists (within 28 weeks)

Recruiting US locations

Study contacts (from the official record)

  • UCB Cares · +18445992273 · ucbcares@ucb.com
  • UCB Cares · +18445992273
All dermatology studies in Arizona →
A Study to Learn if Bimekizumab Given in Different Ways is Safe… (NCT07290036) | Bored Studies